Zeprumetostat: First Approval
Author:
- 18 December 2025
- journal article
- other
- Published by Springer Nature in Drugs
- Vol. 86 (3) , 391-396
Abstract
Abstract Zeprumetostat (艾瑞璟), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd for the treatment of solid and haematological malignancies. In August 2025, zeprumetostat received conditional approval in China for use in adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) who have received ≥ 1 line of systemic therapy. This article summarizes the milestones in the development of zeprumetostat leading to this first approval for the treatment of r/r PTCL.This publication has 14 references indexed in Scilit:
- EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphomaCell Death & Disease, 2025
- Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donorsInternational Immunopharmacology, 2025
- 61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)Hematological Oncology, 2025
- Treating human cancer by targeting EZH2Genes & Diseases, 2025
- Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase 2 trial.Journal of Clinical Oncology, 2024
- Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I StudyClinical Cancer Research, 2024
- Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.Journal of Clinical Oncology, 2023
- SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trialThe Lancet Haematology, 2022
- Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphomaThe Lancet Haematology, 2022
- EZH2 in normal hematopoiesis and hematological malignanciesOncotarget, 2015